Divi's Laboratories Limited (BOM:532488)
India · Delayed Price · Currency is INR | Market Cap | 1.74T +8.8% |
| Revenue (ttm) | 105.60B +12.8% |
| Net Income | 25.68B +17.2% |
| EPS | 96.75 +17.2% |
| Shares Out | n/a |
| PE Ratio | 67.75 |
| Forward PE | 57.03 |
| Dividend | 30.00 (0.44%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 2,728 |
| Open | 6,765.00 |
| Previous Close | 6,660.20 |
| Day's Range | 6,540.00 - 6,765.00 |
| 52-Week Range | 5,637.50 - 7,077.70 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 7,055.50 (+7.69%) |
| Earnings Date | May 23, 2026 |
About Divi's Laboratories
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its pro... [Read more]
Financial Performance
In fiscal year 2026, Divi's Laboratories's revenue was 105.60 billion, an increase of 12.82% compared to the previous year's 93.60 billion. Earnings were 25.68 billion, an increase of 17.21%.
Financial StatementsNews
Top stocks for trade today, May 25: Hindalco Industries, Torrent Pharma, Divi’s Lab, Eicher Motors, NTPC Green and more
Indian equity markets are likely to track several earnings-driven and corporate-specific developments on May 25. Companies including Hindalco Industries, Torrent Pharmaceuticals, Divi's Laboratories, ...
Divi's Laboratories Transcript: Q4 25/26
Q4 and FY26 saw strong revenue and profit growth, stable generics volumes, and robust custom synthesis and peptide pipelines. Despite global supply chain disruptions and rising costs, production and supply reliability were maintained, with a double-digit revenue growth outlook for FY27.
Divi's Laboratories Quarterly report: Q4 2026
Divi's Laboratories has published its Q4 2026 quarterly earnings report on May 23, 2026.
Divi’s Laboratories Q4 Results: Net profit rises 13.4% YoY to Rs 751 crore, revenue up 9.5%
Divi's Laboratories reported a healthy set of earnings for the fourth quarter of FY26, supported by steady revenue growth and improved profitability on a year-on-year basis. The company also announced...
Top Q4 results today, May 23: NTPC, Divi's Laboratories, JK Cement, Reliance Infrastructure among key companies to announce earnings
More than 75 companies are scheduled to announce their Q4FY26 earnings on May 23, making it one of the busiest days of the ongoing earnings season. Key companies set to…
Pharma sector stocks today, March 12: Divi's Laboratories down 1.87%, Abbott India drops 1.51%, Aarti Drugs falls 1.36%
The Indian pharmaceutical sector experienced a decline on March 12, 2026, with most listed stocks trading lower in early morning sessions. The S&P BSE HEALTHCARE Index stood at 43,421.7, down…
M&M, Lenskart & more: Stocks to watch out for today
CLSA raised M&M's target price, expecting 20% EBITDA CAGR driven by strong utility vehicle leadership and a robust launch pipeline. HSBC initiated a buy on Hindalco, citing management's confidence in ...
Divi's Laboratories Transcript: Q3 25/26
Q3 FY26 saw strong revenue and profit growth, driven by custom synthesis and stable generics volumes, despite ongoing pricing pressures. Backward integration, capacity expansion, and a robust export mix supported performance, with major custom synthesis projects set for commercialization in late 2027.
Divi's Laboratories Quarterly report: Q3 2026
Divi's Laboratories has published its Q3 2026 quarterly earnings report on February 11, 2026.
What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q3 2026 Earnings
What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q3 2026 Earnings
Pharma sector stocks today, Feb 10: Pfizer rally 9%, GSK Pharma up 4.12%, Divis Laboratories rises 1.47%
The Indian pharmaceutical sector showed mixed performance on February 10, 2026, as of around 10:05 AM IST. The data provided...
Voltas, HCL Tech & more: Stocks to look out for today; check details
Nuvama downgraded Voltas citing weak near-term demand and high inventory, while Kotak sees improvement in SBI Cards' asset quality and spending. CLSA expects Dalmia Bharat's volumes to rise but margin...
Nykaa, Bajaj Auto & more: Top stocks on brokers' radar today
Analysts have downgraded Trent, citing weak consumption and competition, while Morgan Stanley maintains an overweight rating on Nykaa, impressed by its beauty and fashion business growth. Goldman Sach...
Divi's Laboratories Transcript: Q2 25/26
Q2 FY2026 saw 17% YoY revenue growth, record custom synthesis revenue, and stable generics volumes despite pricing pressure. CapEx will exceed INR 2,000 crore for FY2026, with major investments in capacity and technology. Gross margin remains stable at ~60% as product mix shifts toward custom synthesis.
Divi's Laboratories Quarterly report: Q2 2026
Divi's Laboratories has published its Q2 2026 quarterly earnings report on November 7, 2025.
What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q2 2026 Earnings
What To Expect From Divi's Laboratories Ltd (NSE:DIVISLAB) Q2 2026 Earnings
Muhurat Trading 2025: Top stocks to buy in Samvat 2082 for up to 30% returns; check list
As India celebrates Samvat 2082, LKP Securities unveils its top stock picks for Muhurat Trading, anticipating up to 30% gains. The brokerage highlights Bajaj Finance, Divi's Laboratories, FSN E-Commer...
Top stocks to buy today: Stock recommendations for August 25, 2025
Citigroup recommends buying Divis Laboratories, citing reasonable valuations and sector tailwinds. JP Morgan maintains an underweight rating on Mazgaon Dockyard due to weak quarterly numbers and order...
Stocks to watch on brokerage calls, Aug 7: Bajaj Auto, Bharat Forge, Britannia Industries, Bharti Airtel, Trent, Divis Laboratories and Bajaj Finance
Brokerage notes signal mixed outlook across sectors; Bajaj Auto, Trent and Bharti Airtel in sharp focus after earnings revisions
Divi's Laboratories Transcript: Q1 25/26
Q1 FY26 saw strong revenue and profit growth, driven by robust custom synthesis and operational resilience despite ongoing pricing pressures in generics. Major CapEx is underway, with new facilities and advanced capabilities positioning for future growth.
Divi's Laboratories Quarterly report: Q1 2026
Divi's Laboratories has published its Q1 2026 quarterly earnings report on August 6, 2025.
Morgan Stanley maintains overweight on Divis Labs, sees 11% upside after second global order win
Morgan Stanley has maintained its Overweight rating on Divis Laboratories, with a target price of ₹7,185, implying a 10.8% upside from the current market price of ₹6,482.50. The call comes after Divis...
Divis Laboratories signs long-term supply deal with global pharma company
Divis Laboratories has recently informed exchanges that the company entered into a long-term manufacturing and supply agreement with a global pharmaceutical company. This international agreement marks...
BHEL, Hyundai & more: Top stocks on brokers' radar today
Equirus downgraded Protean eGovernance due to losing a key government project, impacting revenue significantly. Jefferies maintains a hold on Divis Laboratories, citing patent challenges and valuation...
Stocks in news today: Divis Labs, Delhivery, Premier Energies, Zen Tech, KRBL, Galaxy Surfactants, Kaynes Tech after Q4 earnings on May 19
A series of Q4 earnings results released across sectors have highlighted key performers and corporate actions that could drive market sentiment. Here are the major updates from the companies that anno...